Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
Phase 2
Completed
- Conditions
- Dengue Fever
- Interventions
- Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Biological: TDV Placebo
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1800
- Registration Number
- NCT02302066
- Locations
- 🇵🇭
Dela Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines
🇩🇴Hospital Maternidad Nuestra Senora de la Altagracia, Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic
🇵🇦Centro De Vacunacion Internacional, S.A.(CEVAXIN), Ciudad de Panama, Panama
An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 13
- Registration Number
- NCT02302092
Postmarketing Clinical Study on AO-128
Phase 4
Completed
- Conditions
- Impaired Glucose Tolerance (IGT)
- Interventions
- Drug: AO-128
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 197
- Registration Number
- NCT02287402
TAK-114 Single- and Multiple-Dose Phase 1 Study
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- Drug: TAK-114 10 mg capsuleDrug: TAK-114 matched placebo
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 82
- Registration Number
- NCT02286518
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Phase 3
Terminated
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Drug: PioglitazoneDrug: Placebo
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT02284906
Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).Drug: Omega-3 fatty acid ethyl esters
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15330
- Registration Number
- NCT02285166
A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 341
- Registration Number
- NCT02277691
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
Phase 3
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- Drug: SYR-322-MET
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02276274
TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-TAK-385 Oral SolutionDrug: TAK-385 TabletsDrug: [14C]-TAK-385 Solution for Intravenous Infusion
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02252354
Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 964
- Registration Number
- NCT02221284
© Copyright 2025. All Rights Reserved by MedPath